{"id":"W4290719500","doi":"10.1200/po.22.00165","title":"Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Afatinib; Medicine; Internal medicine; Oncology; Cancer; Breast cancer; Targeted therapy; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Gefitinib; Estrogen receptor; Epidermal growth factor receptor; Phases of clinical research; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00231743,0.002043345,0.002456648,0.0003257947,0.0004699086,0.001220406,0.0008100044,0.001453641,0.003843258],"category_scores_gemma":[0.00138909,0.0006138954,0.001352626,0.0003793233,0.0008775473,0.001134158,0.0004086476,0.002924185,0.001030465],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001305553,"about_ca_system_score_gemma":0.00154862,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008853555,"about_ca_topic_score_gemma":0.002241847,"domain_scores_codex":[0.9993917,0.0003184898,0.00003042994,0.00009354452,0.00005116971,0.0001146738],"domain_scores_gemma":[0.9990195,0.0001485851,0.0001774509,0.00006555166,0.00006224871,0.0005265634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.820624,0.04670722,0.01328601,0.001220013,0.002185225,0.0005843698,0.0006175869,0.004354981,0.02858993,0.0006550257,0.01223173,0.06894393],"study_design_scores_gemma":[0.8059049,0.1730249,0.01325838,0.0000394895,0.0003320791,0.0005223032,0.00007550152,0.001405471,0.001991062,0.0003838102,0.003025851,0.00003623328],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859775,0.003234706,0.0008864027,0.001146385,0.000220718,0.003767578,0.002281329,0.00009142973,0.002393931],"genre_scores_gemma":[0.9874827,0.001642032,0.00146919,0.00104203,0.0001837941,0.002803127,0.003057971,0.00003870232,0.002280482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003843258,"threshold_uncertainty_score":0.01285696,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06288459229454123,"score_gpt":0.4389085319902534,"score_spread":0.3760239396957122,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}